2016 American Transplant Congress
Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with a Moderate Splenic B-Cell Reduction.
Comprehensive Transplantation Center/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
Background Bruton tyrosine kinase (Btk) is specifically required for activation of the B-cell antigen receptor signaling pathway that contributes to the initiation and maintenance of…2016 American Transplant Congress
Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.
Background: Medication non-adherence (MNA) is a significant contributor to late graft loss in kidney transplant recipients. The aim of this study was to develop and…2016 American Transplant Congress
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.
In this exploratory biomarker sub-study, a comprehensive combined targeted/ non-targeted metabolomics and targeted proteomics approach was used to assess potential differences between the everolimus+ low-dose…2016 American Transplant Congress
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.
Cardiology, University of California-Los Angeles, Los Angeles, CA.
Purpose: The presence of circulating HLA antibodies which is termed allosensitization among heart transplant (HTx) candidates are associated with poorer posttransplant outcomes including increased morbidity…2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression.
Human bone marrow derived MSC-17 are superior T cell immunomodulators for allotransplantation. Untreated-MSC (UT-MSC) or 5 days IFNγ (MSCγ) or IL-17A (MSC-17) treated MSC were…2016 American Transplant Congress
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.
Surgery, University of Wisconsin, Madison, WI.
Background: Nephrotoxic side effects of calcineurin inhibitors (CNI) have been well established. The addition of anti-metabolites (AM) to CNI-based immunosuppression (IS) regimens has been proposed…2016 American Transplant Congress
The UK ONE Study: Safety and Feasibility of Regulatory T Cell Therapy in Renal Transplantation.
Introduction: The UK ONE Study trial investigates the safety and feasibility of regulatory T (Treg) cell therapy in renal transplantation.Materials and Methods: Eleven (9m;2f) living…2016 American Transplant Congress
Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.
Background: Immunosuppressive therapies are probably the most important cause of hyperlipidemia post-renal transplantation (RTx). Lipid abnormalities represent important biomarkers for cardiovascular (CV) risk. Here, we…2016 American Transplant Congress
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study.
The NEVERWOUND study was designed to evaluate the impact of immediate vs. delayed introduction of everolimus (EVR) on wound healing complications (WHC) and delayed graft…
- « Previous Page
- 1
- …
- 100
- 101
- 102
- 103
- 104
- …
- 138
- Next Page »